- Home
- MRSN vs DIT Comparison
MRSN vs DIT Comparison
Compare MRSN & DIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- DIT
- Stock Information
- Founded
- MRSN 2001
- DIT 1981
- Country
- MRSN United States
- DIT United States
- Employees
- MRSN N/A
- DIT N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- DIT Food Distributors
- Sector
- MRSN Health Care
- DIT Consumer Discretionary
- Exchange
- MRSN Nasdaq
- DIT Nasdaq
- Market Cap
- MRSN 71.9M
- DIT 78.7M
- IPO Year
- MRSN 2017
- DIT 1995
- Fundamental
- Price
- MRSN $0.34
- DIT $117.31
- Analyst Decision
- MRSN Buy
- DIT
- Analyst Count
- MRSN 3
- DIT 0
- Target Price
- MRSN $4.00
- DIT N/A
- AVG Volume (30 Days)
- MRSN 3.1M
- DIT 217.0
- Earning Date
- MRSN 03-03-2025
- DIT 04-17-2025
- Dividend Yield
- MRSN N/A
- DIT 0.84%
- EPS Growth
- MRSN N/A
- DIT N/A
- EPS
- MRSN N/A
- DIT 5.93
- Revenue
- MRSN $40,497,000.00
- DIT $2,202,495,291.00
- Revenue This Year
- MRSN N/A
- DIT N/A
- Revenue Next Year
- MRSN N/A
- DIT N/A
- P/E Ratio
- MRSN N/A
- DIT $20.06
- Revenue Growth
- MRSN 9.88
- DIT 7.62
- 52 Week Low
- MRSN $0.34
- DIT $115.37
- 52 Week High
- MRSN $4.64
- DIT $187.00
- Technical
- Relative Strength Index (RSI)
- MRSN 29.11
- DIT 39.93
- Support Level
- MRSN $0.41
- DIT $115.37
- Resistance Level
- MRSN $0.42
- DIT $125.48
- Average True Range (ATR)
- MRSN 0.04
- DIT 2.90
- MACD
- MRSN -0.00
- DIT -0.82
- Stochastic Oscillator
- MRSN 3.43
- DIT 13.22
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About DIT AMCON Distributing Company
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores, and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.